valproic acid has been researched along with Skin Neoplasms in 7 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase I/II trial of valproic acid (VPA) and KTN was conducted in patients with stage IV melanoma, with any number of prior therapies, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function." | 9.14 | Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. ( Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM, 2009) |
| "Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells." | 7.96 | Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. ( Asgari, MM; Chavez, A; Darbinian, J; Quesenberry, CP, 2020) |
| " A phase I/II trial of valproic acid (VPA) and KTN was conducted in patients with stage IV melanoma, with any number of prior therapies, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function." | 5.14 | Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. ( Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM, 2009) |
| "Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells." | 3.96 | Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. ( Asgari, MM; Chavez, A; Darbinian, J; Quesenberry, CP, 2020) |
| " When valproic acid is combined with tazarotene or isotretinoin, it does not change their photocarcinogenicity significantly." | 1.35 | Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice. ( Lerche, CM; Philipsen, PA; Sehested, M; Wulf, HC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chavez, A | 1 |
| Quesenberry, CP | 1 |
| Darbinian, J | 1 |
| Asgari, MM | 1 |
| Jennings, VA | 1 |
| Scott, GB | 1 |
| Rose, AMS | 1 |
| Scott, KJ | 1 |
| Migneco, G | 1 |
| Keller, B | 1 |
| Reilly, K | 1 |
| Donnelly, O | 1 |
| Peach, H | 1 |
| Dewar, D | 1 |
| Harrington, KJ | 1 |
| Pandha, H | 1 |
| Samson, A | 1 |
| Vile, RG | 1 |
| Melcher, AA | 1 |
| Errington-Mais, F | 1 |
| Guzmán-Sánchez, D | 1 |
| Asz-Sigall, D | 1 |
| Al-Kzayer, LF | 1 |
| Keizer, P | 1 |
| Abdulraheem, FT | 1 |
| Sano, K | 1 |
| Kamata, M | 1 |
| Sakashita, K | 1 |
| Habbaba, LA | 1 |
| Koike, K | 1 |
| Lerche, CM | 1 |
| Philipsen, PA | 1 |
| Sehested, M | 1 |
| Wulf, HC | 1 |
| Daud, AI | 1 |
| Dawson, J | 1 |
| DeConti, RC | 1 |
| Bicaku, E | 1 |
| Marchion, D | 1 |
| Bastien, S | 1 |
| Hausheer, FA | 1 |
| Lush, R | 1 |
| Neuger, A | 1 |
| Sullivan, DM | 1 |
| Munster, PN | 1 |
| Valentini, A | 1 |
| Gravina, P | 1 |
| Federici, G | 1 |
| Bernardini, S | 1 |
2 reviews available for valproic acid and Skin Neoplasms
| Article | Year |
|---|---|
Alopecias due to drugs and other skin and systemic disorders.
Topics: Alopecia; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Dermatologic Agents; Dermat | 2015 |
Rapidly progressive Kaposi's Sarcoma in an Iraqi boy received Valproic acid: a case report and review of literature.
Topics: Anticonvulsants; Child; Disease Progression; Fatal Outcome; Humans; Immunosuppressive Agents; Iraq; | 2016 |
1 trial available for valproic acid and Skin Neoplasms
| Article | Year |
|---|---|
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
4 other studies available for valproic acid and Skin Neoplasms
| Article | Year |
|---|---|
Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Histone Deacetylase Inhibitors; Humans; | 2020 |
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Immunological; Biological Products; Cell Survival; Dendri | 2019 |
Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice.
Topics: Administration, Cutaneous; Animals; Carcinogens; Dermatologic Agents; Dose-Response Relationship, Ra | 2008 |
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Etoposide; Genes, p16; Humans; Melano | 2007 |